Sotera Health (NASDAQ:SHC) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sotera Health (NASDAQ:SHC) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $15.70.

Several research firms have issued reports on SHC. Barclays lifted their price target on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research note on Tuesday, August 6th. Finally, Piper Sandler assumed coverage on Sotera Health in a research note on Tuesday, May 21st. They issued a “neutral” rating and a $13.00 price target for the company.

Hedge Funds Weigh In On Sotera Health

A number of institutional investors have recently modified their holdings of the stock. CWM LLC raised its position in Sotera Health by 86.1% during the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after acquiring an additional 993 shares in the last quarter. Acadian Asset Management LLC boosted its position in Sotera Health by 728.0% in the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after purchasing an additional 8,248 shares in the last quarter. Sandia Investment Management LP purchased a new stake in Sotera Health in the 1st quarter worth approximately $120,000. Securian Asset Management Inc. boosted its position in Sotera Health by 23.0% in the 1st quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock worth $122,000 after purchasing an additional 1,900 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new stake in Sotera Health in the 2nd quarter worth approximately $125,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Price Performance

Shares of SHC stock opened at $14.29 on Tuesday. The stock’s 50-day moving average is $12.60 and its 200 day moving average is $12.82. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The company has a debt-to-equity ratio of 5.46, a current ratio of 2.93 and a quick ratio of 2.86. The company has a market cap of $4.05 billion, a P/E ratio of 75.21 and a beta of 2.06.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Monday, August 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.15 by $0.04. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The business had revenue of $277.00 million during the quarter, compared to analyst estimates of $266.45 million. During the same period in the prior year, the firm posted $0.19 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Research analysts predict that Sotera Health will post 0.64 earnings per share for the current fiscal year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.